This Week in Otolaryngology — Jul 9, 2026

Welcome to This Week in Otolaryngology. This week we're covering 10 notable papers spanning pediatric hearing and safety, new laryngology and rhinology interventions, and critical decision-making in head and neck oncology. Let's dive in.

We begin this week with important updates in otology and pediatric hearing, looking at the timing of intervention, diagnostic screening, and the comparative efficacy of treatments for complex inner ear disorders.

First, a multi-institutional retrospective cohort study in Otology & Neurotology evaluated spoken language outcomes in congenitally deaf children who underwent cochlear implantation. Led by Patel and colleagues, this study analyzed data from 2017 to 2025 across nine cochlear implant centers and schools, focusing on one hundred forty children with bilateral congenital severe-to-profound sensorineural hearing loss implanted before twenty-four months of age. The researchers utilized the Social Vulnerability Index to assess sociodemographic status. Roughly fifty-eight percent of patients were implanted early, meaning before twelve months, while forty-two percent were implanted late, between twelve and twenty-four months. Standardized, age-normed language assessments at age three revealed that the early group had a significantly higher mean total language score of ninety-four point zero compared to seventy-three point four in the late group. A sub-analysis of the early cohort showed that infants implanted before nine months achieved a mean score of one hundred point two, compared to eighty-eight point five for those implanted between nine and twelve months. Although the Social Vulnerability Index was not associated with age at implantation, multivariable regression showed that both the index and age at implantation were independently associated with total language scores. This highlights that implanting infants as early as possible, ideally before nine months, significantly improves spoken language outcomes [1].

Staying with pediatric hearing, a population-based cohort study in JAMA Otolaryngology–Head & Neck Surgery investigated dried blood spot testing for identifying newborns with congenital cytomegalovirus. Kfoury and colleagues analyzed thirteen thousand seventy-eight newborns from twenty-six birth hospitals in Utah, identifying eighty babies with congenital cytomegalovirus via expanded targeted screening. Testing neonatal dried blood spots for viral DNA using a polymerase chain reaction assay demonstrated an overall sensitivity of eighty-six point three percent, a specificity of ninety-nine point five percent, and a positive predictive value of one hundred percent. However, sensitivity varied significantly by clinical severity, reaching ninety-two point seven percent for moderate-to-severe symptomatic disease but dropping to seventy-eight point one percent for mild cases. The authors caution against directly extrapolating these results to universal dried blood spot screening, particularly for asymptomatic infants [4].

Moving to adult neurotology, an umbrella review in The Laryngoscope by Chun and colleagues synthesized evidence from twenty-two systematic reviews with meta-analyses on Meniere's disease treatments. Intratympanic gentamicin demonstrated the highest vertigo control rate at eighty-nine percent, though it carried a twenty-three percent rate of subjective hearing reduction. Intratympanic steroids offered more modest benefits with fewer auditory risks. Conservative treatments like oral betahistine and positive pressure therapy showed mixed results, while acupuncture showed symptomatic benefit only as an adjunct. For surgical options, endolymphatic sac decompression achieved seventy-five to eighty-two percent initial vertigo control, which declined over time. Cochlear implants improved speech and tinnitus in patients with profound hearing loss. The authors emphasized that treatment must be individualized and symptom-driven, as much of the supporting evidence remains low-quality [3].

Our next theme addresses pediatric airway safety and surgical risk profiles. A study in The Laryngoscope by Diamond-Pott and colleagues evaluated national trends in pediatric button battery exposures using the National Electronic Injury Surveillance System from 2020 to 2024. Despite public awareness and federal safety legislation, twenty-four thousand eight hundred ninety-one pediatric button battery exposures presented to United States emergency departments. Annual cases rose by seventy percent, increasing from three thousand seven hundred eighty-five in 2020 to six thousand four hundred twenty-four in 2024. When adjusted for the United States pediatric population, the rate increased from five point one to eight point eight per one hundred thousand children. Toddlers aged thirteen to twenty-four months represented over half of all cases. While the proportion of cases requiring admission declined after peaking in 2021, the overall injury burden rose, with older and Black children more likely to be admitted, emphasizing the need for continued surveillance and prevention [5].

Also in The Laryngoscope, Sela and colleagues compared surgical risk profiles for pediatric sialorrhea. Analyzing two hundred ninety-five patients in the National Surgical Quality Improvement Program-Pediatric database from 2012 to 2023, the authors evaluated patients undergoing botulinum toxin injections, salivary duct ligation or re-routing, submandibular gland excision, or combined procedures. Compared to botulinum injections, salivary duct ligation or re-routing was associated with significantly lower odds of pulmonary complications, medical complications, and composite morbidity. Inpatient status and central nervous system abnormalities were independently associated with increased pulmonary complications. The authors note that the higher complication rate with botulinum injections likely reflects patient selection, as injections are often favored for medically fragile children, but these short-term risk profiles remain essential for counseling families [10].

Our third theme highlights new developments in laryngology and rhinology. A retrospective study in Otolaryngology–Head and Neck Surgery evaluated real-time light-guided vocal fold injection for unilateral vocal fold paralysis. Kim and colleagues analyzed three hundred seventy-eight consecutive injections using hyaluronic acid in two hundred fifty-seven patients via the cricothyroid approach. In all cases, the injection was successfully delivered at the intended target under light guidance, with no superficial injections or mucosal penetrations. The average procedure time was under two minutes, and no serious complications occurred. At four weeks, patients demonstrated significant improvements across all voice outcomes, including the Voice Handicap Index-10, the Grade, Roughness, Breathiness, Asthenia, and Strain scale, and maximum phonation time, establishing this as a highly precise and safe office-based technique [6].

In another laryngological intervention, a prospective study in The Laryngoscope investigated selective laryngeal cryotherapy as a sensory neurolytic treatment for refractory neurogenic chronic cough. Dhar and colleagues enrolled thirty patients who underwent awake selective laryngeal cryotherapy. The procedure was highly tolerable, with no serious adverse events, and mild, self-limiting side effects in twenty-one percent of patients. Post-procedure laser sensory testing showed a significant increase in the mean laser power threshold required to trigger a cough, rising from two point eight watts to seven point five watts at one month. By six months, patients demonstrated sustained clinical improvements, with significant reductions in both the Cough Severity Index and the urge to cough visual analog scale, suggesting cryotherapy is a promising option to downregulate laryngeal hypersensitivity [8].

In rhinology, a prospective study in The Laryngoscope assessed the impact of psychological status on five-year outcomes after endoscopic sinus surgery for chronic rhinosinusitis. Zhou and colleagues tracked one thousand sixty-nine patients using the SNOT-22 survey, stratifying them into high and low psychological dysfunction groups based on baseline scores. Five-year data were available for two hundred five patients in the high dysfunction group and one hundred ninety-six in the low dysfunction group. At baseline, the high dysfunction group had significantly worse overall SNOT-22 scores of sixty-one point one compared to thirty-two point eight. While both groups achieved similar relative improvements of roughly forty-five percent at five years, the high dysfunction group maintained significantly worse absolute symptom severity. Multivariable regression revealed that preoperative psychological scores independently predicted worse postoperative non-psychological symptom scores, highlighting the need for preoperative screening to manage patient expectations [9].

Our final theme focuses on clinical decision-making in head and neck oncology. A study in Head & Neck evaluated the impact of adjuvant radiotherapy in pathologically staged T2N0 oral squamous cell carcinoma. Nemade and colleagues conducted a propensity score-matched survival analysis of patients treated between 2015 and 2023. Among four hundred eligible patients, two hundred twenty-six underwent surgery alone and one hundred seventy-four received adjuvant radiotherapy. Propensity matching generated one hundred seven matched pairs, controlling for factors like depth of invasion, perineural invasion, and margin distance. The three-year disease-free survival was seventy-eight point three percent for surgery alone and eighty-two point one percent for surgery plus radiotherapy. This difference was not statistically significant, and adjuvant radiotherapy was not associated with improved survival, suggesting that routine adjuvant radiation may not benefit pathologically staged T2N0 oral cancer without other high-risk features [2].

To aid in risk stratification, an international collaborative study in Head & Neck developed and validated nomograms to predict recurrence after skull base surgery for primary malignant tumors. Valero and colleagues analyzed two thousand one hundred seventy-nine patients, splitting them into training and validation cohorts. The most common sites were the ethmoid, nasal cavity, and maxillary sinuses. Local recurrence was predicted by brain invasion, high-risk histology, advanced T-stage, positive nodal status, and positive margins, while adjuvant therapy was protective. Regional and distant recurrence predictors mirrored these findings. The resulting nomograms achieved a concordance index of approximately zero point seven across all endpoints, providing clinicians with a validated tool to personalize postoperative surveillance and adjuvant treatment decisions [7].

If you only have time for one paper this week, make it the multi-institutional study on spoken language outcomes after early cochlear implantation published in Otology & Neurotology. This study provides strong evidence that implanting congenitally deaf infants before nine months of age significantly improves spoken language scores by age three, setting a clear, actionable target for early intervention programs [1].

Here are the key takeaways from this week in Otolaryngology. First, cochlear implantation in congenitally deaf infants should be performed as early as possible, ideally before nine months of age, to maximize spoken language development. Second, pediatric button battery exposures presenting to United States emergency departments have risen by seventy percent over five years, emphasizing the critical need for continued safety advocacy and rapid clinical intervention. Third, while endoscopic sinus surgery provides substantial five-year quality of life improvements, patients with high baseline psychological dysfunction will continue to experience higher absolute symptom severity postoperatively, indicating that preoperative psychological screening is essential for counseling. Fourth, routine adjuvant radiotherapy does not improve three-year disease-free survival in pathologically staged T2N0 oral squamous cell carcinoma, suggesting it should be reserved for cases with other specific high-risk features. Finally, selective laryngeal cryotherapy is a safe and effective office-based option that downregulates laryngeal hypersensitivity and provides lasting relief for patients with refractory neurogenic chronic cough.

That's your roundup for This Week in Otolaryngology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.